- Home
- EXTR vs XOMAP Comparison
EXTR vs XOMAP Comparison
Compare EXTR & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXTR
- XOMAP
- Stock Information
- Founded
- EXTR 1996
- XOMAP N/A
- Country
- EXTR United States
- XOMAP United States
- Employees
- EXTR N/A
- XOMAP 13
- Industry
- EXTR Telecommunications Equipment
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- EXTR Telecommunications
- XOMAP Health Care
- Exchange
- EXTR Nasdaq
- XOMAP Nasdaq
- Market Cap
- EXTR N/A
- XOMAP N/A
- IPO Year
- EXTR 1999
- XOMAP N/A
- Fundamental
- Price
- EXTR $16.03
- XOMAP $25.78
- Analyst Decision
- EXTR Strong Buy
- XOMAP
- Analyst Count
- EXTR 5
- XOMAP 0
- Target Price
- EXTR $19.00
- XOMAP N/A
- AVG Volume (30 Days)
- EXTR 1.4M
- XOMAP N/A
- Earning Date
- EXTR 10-30-2024
- XOMAP N/A
- Dividend Yield
- EXTR N/A
- XOMAP N/A
- EPS Growth
- EXTR N/A
- XOMAP N/A
- EPS
- EXTR N/A
- XOMAP N/A
- Revenue
- EXTR $1,033,270,000.00
- XOMAP N/A
- Revenue This Year
- EXTR $2.76
- XOMAP N/A
- Revenue Next Year
- EXTR $8.36
- XOMAP N/A
- P/E Ratio
- EXTR N/A
- XOMAP N/A
- Revenue Growth
- EXTR N/A
- XOMAP N/A
- 52 Week Low
- EXTR $10.50
- XOMAP N/A
- 52 Week High
- EXTR $18.77
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- EXTR 55.75
- XOMAP 46.03
- Support Level
- EXTR $15.08
- XOMAP $25.69
- Resistance Level
- EXTR $17.23
- XOMAP $25.98
- Average True Range (ATR)
- EXTR 0.54
- XOMAP 0.13
- MACD
- EXTR -0.07
- XOMAP -0.03
- Stochastic Oscillator
- EXTR 46.90
- XOMAP 16.11
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.